<DOC>
	<DOC>NCT02508506</DOC>
	<brief_summary>This study will evaluate the effect of various degrees of renal function on the pharmacokinetics and safety of ALKS 5461.</brief_summary>
	<brief_title>Pharmacokinetics and Safety of ALKS 5461 in Subjects With Renal Impairment and Normal Renal Function</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>For all subjects: Has a body mass index (BMI) of 18.040.0 kg/m^2 and a total body weight &gt;50kg Agrees to use an approved method of contraception for the duration of the study Additional criteria may apply For subjects with renal impairment: Has severe or end stage renal disease, and does not require dialysis Has stable renal function for at least 60 days preceding screening Additional criteria may apply For all subjects: Has any past history or current finding of a clinically significant observed abnormality, psychiatric or medical condition other than renal impairment Has a history of gastrointestinal surgery affecting drug absorption or biliary elimination, excluding appendectomy or cholecystectomy Is pregnant, planning to become pregnant, or lactating Has a history of clinically significant allergy or a hypersensitivity to opioids Additional criteria my apply For subjects with renal impairment: Has evidence of compromised respiratory function, seizure disorder, or myasthenia gravis Has received a kidney transplant Additional criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>ALKS 5461</keyword>
	<keyword>Alkermes</keyword>
	<keyword>Samidorphan</keyword>
	<keyword>Renal Impairment</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Buprenorphine</keyword>
</DOC>